Recent Updates
Recently added Catalysts
MNKD Positive Sentiment

MannKind to Present at Jefferies Global Healthcare Conference

Key Takeaway: MannKind Corporation announced that its CEO, Michael Castagna, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3. The event will be accessible via a live audio webcast on the company's website, with recorded versions available for 90 days post-conference. MannKind is dedicated to developing treatments for chronic diseases.
Price reaction · baseline $3.53 (2026-05-26 close) · hit after-hours · 2 other MNKD headline(s) in the window, move may be shared
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • MannKind's CEO will present at a prominent healthcare conference.
  • The company focuses on innovative solutions for chronic diseases.
  • MannKind has a commitment to addressing serious unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.1%
average across 14 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Fursemide for administration
Phase 2 · Heart Failure

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) --MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKindMannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.

Frequently Asked Questions

When will MannKind's CEO present at the conference?

Michael Castagna will present on June 3 at 9:20 a.m. ET.

Where can I watch the MannKind presentation?

The presentation will be available via a live audio webcast on MannKind's website.

How long will the recorded presentation be available?

Recorded versions will be available for approximately 90 days after the conference.

What diseases does MannKind focus on?

MannKind focuses on cardiometabolic and orphan lung diseases.

Last updated: May 27, 2026